V
Vanda Pharmaceuticals D
D
VNDA
4.37000
USD
-0.07
(-1.47%)
مغلق
حجم التداول
8,451
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
258,219,498
الأخبار المقالات
العنوان: Vanda Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.